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OBJECTIVE: The cost-effectiveness of bone mineral density
(BMD) screening and hormone replacement therapy for in-
dividuals with osteoporosis and osteopenia are well docu-
mented. The objective of this study was to estimate the eco-
nomic impact of administering supplemental calcium and
vitamin D3 to post-menopausal women with unknown
BMD but such easily identifiable risk factors as advancing
age, maternal family history of hip fractures, smoking, and
prior fragility fractures after the age of 50 in Sweden.
METHODS: We developed a Markov model for analyz-
ing the occurrence and timing of hip fractures for cohorts
of women (aged 50 to 90), almost entirely based on peer-
reviewed data from Sweden. In a three-year randomized
clinical trial, the combination of calcium and vitamin D3
was shown to reduce the risk of hip fractures by 27 per-
cent. Costs for treating hip fracture were based on 1080
women who were hospitalized in Stockholm.
RESULTS: We estimate that 22 to 23 percent of 50-year-
old women in the general population will experience at
least one hip fracture in their remaining lifetimes if un-
treated. Lifetime intervention with calcium and vitamin
D3 in the general population starting at age 61was esti-
mated to be cost saving. The cumulative incidence and
cost for individuals with a maternal family history, smok-
ing habit, and a prior fragility fracture after the age of 50
were found to be higher than for osteopenia. Lifetime in-
tervention with calcium and vitamin D3 was found to be
cost saving in women as young as their early 50’s.
CONCLUSION: There is a clear role for lifetime calcium
and vitamin D3 treatment in Sweden, with especially strong
support for providing them to women over 60 years old or
to women as young as 50 in the presence of such easily iden-
tifiable risk factors as a maternal family history of hip frac-
tures, a prior fragility fracture or smoking habit.
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OBJECTIVES: Many drugs show long-term rather than
short-term benefits. Moreover, most clinical studies were
too short to give evidence of cost savings. Therefore, we
developed a simulation model to estimate the costs and
benefits of BMI lowering drugs within a time frame of 10
years. We applied this simulation, a Markov model, to
data from 4429 patients (20 studies) treated with the
weight-management agent sibutramine or placebo. Both
groups also received diet and exercise advice.
METHODS: As major savings of lipid and BMI lowering
drugs will be induced by reductions incidence rates for
hypertension, CHD and diabetes (H-CHD-D), we re-
stricted our model to these diseases. We chose a time
frame of 10 years. In order to estimate changes in the in-
cidence rates of H-CHD-D we used risk-equations data
derived from large epidemiological studies. Our Markov
model contains the following disease states: no disease;
only hypertension; diabetes without CHD; CHD, and
death. We estimated the transition probabilities by using
the respective risk equation. Finally, each state was
linked to annual costs. Using this simulation, we could
estimate the individual costs for hypertension, CHD, and
diabetes for each of the patients within the time frame of
10 years. The mean difference in costs between the
sibutramine and placebo groups were considered to be
savings induced by the sibutramine therapy.
RESULTS: The 10-year incidence rates (sibutramine vs.
placebo) were 22.3% vs. 33.8% (hypertension), 4.5% vs.
6.1% (CHD), and 19.4% vs. 21.3% (diabetes). The mean
costs induced by H-CHD-D were 8042 DM for sibutra-
mine and 9671 DM for placebo, a reduction of 1629 DM.
CONCLUSION: Considering annual sibutramine costs
of 912 DM, a net benefit of 717 DM over 10 years per
patient results. This is a conservative estimate as only
three diseases related to obesity were included.
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OBJECTIVE: To determine the cost-effectiveness of
thrombosis prevention with Clopidogrel versus Ticlopi-
dine in Russia.
METHODS: Clinical efficacy of Ticlopidine 250 mg
daily versus Clopidogrel 37,5 mg daily was evaluated in a
comparative clinical trial including 30 days follow-up of
70 patients with thrombophilia. Clinical efficacy was
measured by percentage reduction in spontaneous plate-
let aggregation (SPA) that was considered to be a prog-
nostic indicator for thrombosis. Costs for medication
were calculated. Cost-effectiveness ratio (CER) was de-
fined for both drugs, and incremental cost-effectiveness
ratio (ICER) was determined.
RESULTS: Mean percent SPA reduction from baseline
level was 63,3% in the Clopidogrel group, and 48,8% in
the Ticlopidine group. The mean cost for 30 days of Clo-
pidogrel treatment was 1221 rub (42,1$) compared to
795 rub (27,4$) for Ticlopidine. The CER for Clopi-
dogrel was 19,2 rub (0,66$) per 1% SPA reduction; for
Ticlopedine—16,2 rub (0,56$) per 1% SPA reduction.
ICER for Clopidogrel group versus Ticlopidine group
was 29,17 rub (1,01$) per 1% SPA reduction.
CONCLUSION: Clopidogrel 37,5 mg daily achieved a
greater percentage reduction in SPA than Ticlopidine 250
mg daily. Costs for Clopidogrel were higher than for Ticlo-
pidine, though ICER suggests that additional effect can be
achieved relatively inexpensively. For final conclusion, the
safety of both drugs should be taken into account.
